Abstract
Cerebrospinal fluid (CSF) is being analyzed for the diagnosis of a variety of neurological diseases. Among the methods employed, metabolomics and proteomics are increasingly gaining popularity. At present, sensitivity and, in particular, specificity are limited in CSF metabolomics by nuclear magnetic resonance (NMR) spectroscopy. Nonetheless, progress is being made by studying more and more well-defined and homogeneous patient cohorts. This review starts off with a brief overview of classical CSF analysis in multiple sclerosis (MS), followed by a description of NMR spectroscopy in general metabolic CSF analysis. The subsequent sections focus on metabolomic profiling of CSF by NMR spectroscopy in MS and other neurological disorders. Currently existing results are reviewed and compared, and the potential and limits of this approach are discussed. In addition, several methodological questions are addressed, and the prospects for future developments are briefly outlined.
Keywords: Multiple sclerosis (MS), metabolomics, cerebrospinal fluid (CSF), nuclear magnetic resonance spectroscopy (NMR, MRS), neurological diseases, Cerebrospinal fluid, proteomics, homogeneous patient cohorts, multiple sclerosis, neurological disorders, biomarkers, qualitative and quantitative protein analysis, drug targets
Current Pharmaceutical Biotechnology
Title: Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Volume: 12 Issue: 7
Author(s): N. W. Lutz and P. J. Cozzone
Affiliation:
Keywords: Multiple sclerosis (MS), metabolomics, cerebrospinal fluid (CSF), nuclear magnetic resonance spectroscopy (NMR, MRS), neurological diseases, Cerebrospinal fluid, proteomics, homogeneous patient cohorts, multiple sclerosis, neurological disorders, biomarkers, qualitative and quantitative protein analysis, drug targets
Abstract: Cerebrospinal fluid (CSF) is being analyzed for the diagnosis of a variety of neurological diseases. Among the methods employed, metabolomics and proteomics are increasingly gaining popularity. At present, sensitivity and, in particular, specificity are limited in CSF metabolomics by nuclear magnetic resonance (NMR) spectroscopy. Nonetheless, progress is being made by studying more and more well-defined and homogeneous patient cohorts. This review starts off with a brief overview of classical CSF analysis in multiple sclerosis (MS), followed by a description of NMR spectroscopy in general metabolic CSF analysis. The subsequent sections focus on metabolomic profiling of CSF by NMR spectroscopy in MS and other neurological disorders. Currently existing results are reviewed and compared, and the potential and limits of this approach are discussed. In addition, several methodological questions are addressed, and the prospects for future developments are briefly outlined.
Export Options
About this article
Cite this article as:
W. Lutz N. and J. Cozzone P., Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy, Current Pharmaceutical Biotechnology 2011; 12 (7) . https://dx.doi.org/10.2174/138920111795909122
DOI https://dx.doi.org/10.2174/138920111795909122 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adult Neurogenesis, Neural Stem Cells and Alzheimers Disease: Developments, Limitations, Problems and Promises
Current Alzheimer Research Nose to Brain Delivery of Nanocarriers Towards Attenuation of Demented Condition
Current Pharmaceutical Design The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview
Current Drug Targets Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease
Current Alzheimer Research Risk Reduction and Prevention of Alzheimer's Disease: Biological Mechanisms of Diet
Current Alzheimer Research Review of Synthesis, Assay, and Prediction of β and γ-secretase Inhibitors
Current Topics in Medicinal Chemistry Transgenic Mice as a Model of Pre-Clinical Alzheimers Disease
Current Alzheimer Research Ramelteon in the Treatment of Delirium: New Perspectives from Reported Findings and a Case Observation
Current Drug Therapy Clinical Application of Ghrelin
Current Pharmaceutical Design The Neurobiological Bases for Development of Pharmacological Treatments of Aggressive Disorders
Current Neuropharmacology Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Advances in Drug Discovery to Assess Cholinergic Neurotransmission: A Systematic Review
Current Drug Discovery Technologies Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Subject Index To Volume 7
Current Drug Targets Editorial [Hot Topic: Auditory Processing Disorder (Guest Editors: Vasiliki Maria Iliadou)]
Current Pediatric Reviews Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Intracranial MR Dynamics in Clinically Diagnosed Alzheimers Disease: The Emerging Concept of “Pulse Wave Encephalopathy”
Current Alzheimer Research A Review on the Effects of Testosterone Supplementation in Hypogonadal Men with Cognitive Impairment
Current Drug Targets Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart
Current Pharmaceutical Design